Studies have established the therapeutic potential of SCN2A as a pharmacological target in mitigating the severity of diseases associated with dysfunction of the Nav1.2 channel, such as epilepsy, seizures, and ASD/ID [41,49,50]. This evidence concerns the gene SCN2A and epilepsy.